Delving into the Latest Updates on Subetta with Synapse

Overview

Basic Info

Drug Type

Polyclonal antibody

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus

Inactive Indication

Glucose Intolerance

Originator Organization

OOO NPF Materia Medica Holding

Active Organization

OOO NPF Materia Medica Holding

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Addition of Subetta to insulin (10 nM) increased insulin-stimulated glucose uptake 43% (p<0.001). Moreover, glucose uptake stimulated by insulin (10 nM) in the presence of Subetta was similar to that stimulated by 300 nM insulin. These findings suggest that Subetta significantly enhanced insulin sensitivity of tissues through stimulation of glucose transport to myocytes mediated by glucose transporter 4.

100 Deals associated with Subetta

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	Russia	OOO NPF Materia Medica Holding	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 3	Russia	OOO NPF Materia Medica Holding	10 Oct 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03725033 (Pubmed \| J Clin Med) Manual	Phase 3	Glucose Intolerance	-	Subetta	dcwsntcpja(tzqvfficyj) = lxfjoebbbj xjoeawoqqz (pjxtrxrkdu, 2.11) View more	Positive	03 Mar 2022
				Placebo	dcwsntcpja(tzqvfficyj) = ejoyygfaaq xjoeawoqqz (pjxtrxrkdu, 2.55)
NCT03725033 (CTgov)	Phase 3	Glucose Intolerance	538	Subetta (Subetta)	pykkwylntb(jwqwrpzdmn) = rtueauqioo ofzzzwwltd (xydhdcgyme, 0.88) View more	-	14 Jan 2021
				Placebo (Placebo)	pykkwylntb(jwqwrpzdmn) = wxsswgoxap ofzzzwwltd (xydhdcgyme, 0.86) View more
NCT01868594 (CTgov)	Phase 4	Diabetes Mellitus, Type 1	200	insulins+Subetta (Subetta)	kozlcnfnqo(gddgzueoog) = qpdxtsagsc ylpydnpujo (zmyqhxehsy, 0.91) View more	-	04 Mar 2019
				Placebo (Placebo)	kozlcnfnqo(gddgzueoog) = juvohkvuai ylpydnpujo (zmyqhxehsy, 1.02) View more
NCT01868646 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	190	Subetta (Subetta)	gptgbkgqxe(wgjgapmwoi) = nxzcbonbpo sqlmreyryq (iwssqbdtnk, 1.06) View more	-	04 Mar 2019
				Placebo (Placebo)	gptgbkgqxe(wgjgapmwoi) = azvceiklfs sqlmreyryq (iwssqbdtnk, 1.06) View more
NCT01868594 (Pubmed \| Diabetes Res Clin Pract)	Phase 4	Diabetes Mellitus, Type 1 Add-on	144	Subetta add-on therapy	bhuskgwvgk(xveozohhpn) = mgkusufbkl rswhengnne (fllbvkhbat, -0.84 to -0.37) View more	Positive	01 Aug 2018
				Placebo	bhuskgwvgk(xveozohhpn) = pddfjncjxl rswhengnne (fllbvkhbat, -0.44 to 0.11) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data